Wolfe Research initiated coverage of Stoke Therapeutics (STOK) with an Outperform rating and $40 price target The firm launched coverage of the neuroscience biotech sector with a “portfolio of high conviction names across multiple therapeutic areas.” Wolfe says Stoke’s STK-001 could be approved as the first disease-modifying therapy for Dravet syndrome.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics participates in a conf call hosted by Cantor Fitzgerald
- Stoke Therapeutics initiated with a Buy at Guggenheim
- Stoke Therapeutics Expands with New Long-Term Waltham Headquarters
- Stoke Therapeutics price target raised to $36 from $32 at Wedbush
- Stoke Therapeutics Accelerates Phase 3 Dravet Study Timeline